TY - JOUR
T1 - Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy
AU - Stanton, Christopher
AU - Mookadam, Farouk
AU - Cha, Stephen
AU - McNamara, Dennis
AU - Aukrust, Pål
AU - Wojnicz, Romwald
AU - Bailey, Kent R.
AU - Cooper, Leslie T.
PY - 2008/8/1
Y1 - 2008/8/1
N2 - Background: Persistent inflammation contributes to cardiac dysfunction in chronic dilated cardiomyopathy (DCM). Trials of immunomodulatory therapy for DCM have been limited by small sample size and yielded conflicting results. We hypothesized that clinical response to immunomodulation would be dependent on symptom duration. Pooled immunomodulatory trial data was used to test this hypothesis. Methods: Data from 130 subjects in 3 randomized, placebo-controlled trials of immunomodulatory therapy in DCM were combined and prospectively analyzed to evaluate change in left ventricular ejection fraction (LV-EF) at 6 and 12 months after randomization by Wilcoxon Rank-Sum test. Logistic regression analysis evaluated correlations between age, gender, symptom duration and change in LV-EF. Results: Patients ≥ 6 months of symptoms before immunomodulatory therapy had a greater increase in LV-EF at 6 and 12 months than those receiving placebo (14.4% vs. 4.4%, p < 0.001 and 19.5% vs. 5.6%, p < 0.001, respectively). Patients with < 6 months of symptoms had a similar increase in LV-EF compared to subjects treated with placebo (14.3% vs. 13.3%, p = 0.84 and 14.8% vs. 15.2%, p = 0.74, respectively). Older age and male gender were not associated with LV-EF change. Conclusion: Immunomodulatory therapy is associated with improved LV-EF in DCM patients with ≥ 6 or more months of symptom duration.
AB - Background: Persistent inflammation contributes to cardiac dysfunction in chronic dilated cardiomyopathy (DCM). Trials of immunomodulatory therapy for DCM have been limited by small sample size and yielded conflicting results. We hypothesized that clinical response to immunomodulation would be dependent on symptom duration. Pooled immunomodulatory trial data was used to test this hypothesis. Methods: Data from 130 subjects in 3 randomized, placebo-controlled trials of immunomodulatory therapy in DCM were combined and prospectively analyzed to evaluate change in left ventricular ejection fraction (LV-EF) at 6 and 12 months after randomization by Wilcoxon Rank-Sum test. Logistic regression analysis evaluated correlations between age, gender, symptom duration and change in LV-EF. Results: Patients ≥ 6 months of symptoms before immunomodulatory therapy had a greater increase in LV-EF at 6 and 12 months than those receiving placebo (14.4% vs. 4.4%, p < 0.001 and 19.5% vs. 5.6%, p < 0.001, respectively). Patients with < 6 months of symptoms had a similar increase in LV-EF compared to subjects treated with placebo (14.3% vs. 13.3%, p = 0.84 and 14.8% vs. 15.2%, p = 0.74, respectively). Older age and male gender were not associated with LV-EF change. Conclusion: Immunomodulatory therapy is associated with improved LV-EF in DCM patients with ≥ 6 or more months of symptom duration.
KW - Dilated cardiomyopathy
KW - Heart failure
KW - Immunoglobulin
KW - Immunosuppression
UR - http://www.scopus.com/inward/record.url?scp=46149117759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46149117759&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2007.05.016
DO - 10.1016/j.ijcard.2007.05.016
M3 - Article
C2 - 17707091
AN - SCOPUS:46149117759
SN - 0167-5273
VL - 128
SP - 38
EP - 41
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 1
ER -